Because of ease of establishing a syngeneic lymphoma transplantation model, a type of the GEM-derived allograft (GDA) model (17), the Eμ-Myc;Cdkn2a−/− cell line, which usually gives rise to lymphoma in lymph nodes, is widely used for in vivo efficacy evaluation (18, 19). The gene discussed is CDKN2A; the disease is lymphoma.